The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
An Updated Focused Review of Dexmedetomidine in Adults
Abstract
Objective: To evaluate recent comparative studies regarding the safety and efficacy of dexmedetomidine in adults. Data Sources: Articles evaluating safety and efficacy of dexmedetomidine were identified from an English-language MEDLINE search (1996–July 2009), with a focus on data published since our previous review in 2007 to the present. MeSH terms included dexmedetomidine, medetomidine, α 2:-agonist, and sedation. References from selected articles were also reviewed for additional material. Study Selection and Data Extraction: Experimental and observational English-language studies that focused on the efficacy, safety, and pharmacoeconomics of dexmedetomidine in humans were selected. Data Synthesis: Dexmedetomidine is an α 2-agonist used for sedation during procedures and in critical illness. Compared with placebo, use of dexmedetomidine during procedures was associated with decreased use of rescue midazolam and a similar degree of sedation compared with various agents used during surgery or for procedures. Use of long-term (>24 h) dexmedetomidine sedation is comparable to sedation with benzodiazepines in critically ill patients. In a Phase 4 study, dexmedetomidine was safe in dosages up to 1.4 μg/kg/hour for greater than 24 hours and did not produce rebound tachycardia or hypertension when abruptly discontinued. One small randomized controlled trial demonstrated decreased incidence of delirium, the primary endpoint, with dexmedetomidine compared with midazolam or propofol for sedation after cardiac valve surgery. Many, but not all, studies suggest that dexmedetomidine has a promising role in prevention and treatment of delirium in critically ill patients when delirium was studied as a secondary endpoint. Conclusions: Dexmedetomidine is an alternative for procedural sedation and can be used long-term (>24 h) in critically ill patients, in dosages up to 1.5 μg/kg/hour. More studies are needed to better define the role of dexmedetomidine in preventing and treating delirium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ely, E. W., Inouye, S. K., Bernard, G. R., Gordon, S., Francis, J., May, L., Truman, B., Speroff, T., Gautam, S., Margolin, R., et al. (2001) · JAMA · doi:10.1001/jama.286.21.2703 · Cited by 3,210
Delirium as a Predictor of Mortality in Mechanically Ventilated Patients in the Intensive Care Unit
Ely, E. W. (2004) · JAMA · doi:10.1001/jama.291.14.1753 · Cited by 3,073
Intensive Care Delirium Screening Checklist: evaluation of a new screening tool
Bergeron, N., Dubois, M.-J., Dumont, M., Dial, S., & Skrobik, Y. (2001) · Intensive Care Medicine · doi:10.1007/s001340100909 · Cited by 1,487
Cited by
Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine
Weerink, M. A. S., Struys, M. M. R. F., Hannivoort, L. N., Barends, C. R. M., Absalom, A. R., & Colin, P. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0507-7 · Cited by 1,208
Brummett, C. M., Hong, E. K., Janda, A. M., Amodeo, F. S., & Lydic, R. (2011) · Anesthesiology · doi:10.1097/aln.0b013e318221fcc9 · Cited by 321
Role of α 2 -Agonists in the Treatment of Acute Alcohol Withdrawal
Muzyk, A. J., Fowler, J. A., Norwood, D. K., & Chilipko, A. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p575 · Cited by 107
Metadata
- Authors
- Gerlach, A. T., Murphy, C. V., & Dasta, J. F.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2009-11-25
- Volume
- 43
- Issue
- 12
- Pages
- 2064-2074
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2145116310
- Cited by
- 200
- References
- 3
- FWCI
- 11.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Updated Focused Review of Dexmedetomidine in Adults. https://app.cochat.ai/papers/10.1345/aph.1m310
- The paper
- Gerlach, A. T., Murphy, C. V., & Dasta, J. F. (2009). An Updated Focused Review of Dexmedetomidine in Adults. Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1m310
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.